GET DAILY SIGNALSSanofi (SNY) Reports Strong Q3 2026 Results with Guidance Raised Again
Key Takeaways
- Sanofi reported third-quarter 2026 net sales of €14,444 million, up 16.2% on a reported basis and 14.3% at constant exchange rates (CER, which strips out currency movements).
- Business earnings per share (EPS, a non-IFRS profit measure Sanofi uses to show operational performance) came in at €3.55, up 19.6% at CER and ahead of the roughly €2.79 analysts had expected.
- Dupixent, the company's flagship immunology medicine, grew 34.8% to about €5.7 billion, while sales of newer launched drugs climbed 31.4% to €1.4 billion.
- Vaccines were the main drag, falling 6.6% to €3.2 billion on expected timing shifts in respiratory-prevention products.
- Management raised its full-year 2026 outlook for a second time, now guiding to low-teens sales growth and mid-teens business EPS growth at CER.
- For additional context on Sanofi's Major News, Today's Price Move, Price Targets, and Forecast, explore these dedicated pages for a fuller view of the stock's latest developments.
- You can also discover momentum and signal-based ideas across the market by exploring Trending AI Robots.
Earnings Context and Why It Matters
Sanofi's third-quarter 2026 results arrived at a pivotal moment for the French pharmaceutical giant. Investors are closely watching how the company manages its dependence on Dupixent, which is now generating more than €5 billion in a single quarter, while preparing for that drug's eventual loss of exclusivity early next decade. The quarter also tested Sanofi's ability to sustain cost discipline, broaden its newer product launches, and offset softer vaccine demand. With management signaling that mergers and acquisitions will play a central role in reshaping the portfolio, this report offers a clear read on both near-term execution and the longer-term strategy to protect earnings growth.
Reported Results
Sanofi delivered third-quarter 2026 net sales of €14,444 million, a 16.2% increase on a reported basis and 14.3% at CER, topping the roughly €13.6 billion analysts had projected. Business EPS reached €3.55, up 19.6% at CER and 22.0% at actual exchange rates, comfortably above consensus estimates near €2.79. IFRS net income rose 7.8% to €3,021 million, with IFRS EPS of €2.52.
Growth was led by Dupixent, which climbed 34.8% to about €5.7 billion, and by pharma launches, up 31.4% to €1.4 billion on contributions from ALTUVIIIO, Ayvakit, and Rezurock. Vaccines declined 6.6% to €3.2 billion, reflecting anticipated phasing in respiratory prevention. Research and development expenses were broadly stable at €1.8 billion, while selling and general expenses fell 0.9% to €2.3 billion, underscoring cost discipline. Free cash flow rose 9.2% to €3,269 million. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Market Reaction and Investor Sentiment
The market's initial read on Sanofi's report was broadly constructive, with the results exceeding both revenue and earnings expectations and management upgrading its 2026 guidance. Sentiment heading into the print had been shaped by concerns about Dupixent's concentration risk and softness in the vaccines segment. The better-than-expected Dupixent growth and the second guidance raise helped address those worries, while the confirmed vaccine decline remained a notable offset. Investors also weighed the expanded alliance with Regeneron in immunology and the portfolio-simplification partnership with Cheplapharm as signals that management is actively repositioning the business ahead of Dupixent's loss of exclusivity.
Forward Outlook and Key Factors to Monitor
Following the upgrade, Sanofi now expects full-year 2026 sales to grow in the low-teens percentage range at CER and business EPS to grow in the mid-teens percentage range at CER. That guidance signals management's confidence in sustaining momentum through the remainder of the year, supported by Dupixent and the newer pharma launches.
Looking further ahead, investors will want to monitor the trajectory of Dupixent as it approaches loss of exclusivity, the pace of growth from recently launched medicines, and whether vaccine sales stabilize once the respiratory-prevention phasing normalizes. Cost trends will also matter, given the role of expense discipline in driving the strong business EPS growth.
Management has flagged business development and M&A as critical tools for reshaping the portfolio, so deal activity in immunology and other therapeutic areas is likely to draw attention. Pipeline progress, including regulatory approvals and submissions, will remain another key catalyst as Sanofi works to protect earnings growth into the next decade.
Using AI Tools in My Research Process
In my day-to-day analysis of pharmaceutical names like SNY, I often rely on Tickeron’s AI Screener to quickly filter for comparable companies based on technical patterns, fundamentals, and performance metrics. It helps surface relevant trade ideas and industry benchmarks without the need for manual screening across thousands of stocks. This approach keeps my review of earnings reports more efficient and grounded in data-driven comparisons.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
Momentum Indicator for SNY turns positive, indicating new upward trend
SNY saw its Momentum Indicator move above the 0 level on October 16, 2026. This is an indication that the stock could be shifting in to a new upward move. Traders may want to consider buying the stock or buying call options. Tickeron's A.I.dvisor looked at 99 similar instances where the indicator turned positive. In 57 of the 99 cases, the stock moved higher in the following days. The odds of a move higher are at 58%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Moving Average Convergence Divergence (MACD) for SNY just turned positive on October 15, 2026. Looking at past instances where SNY's MACD turned positive, the stock continued to rise in 22 of 45 cases over the following month. The odds of a continued upward trend are 49%.
SNY moved above its 50-day moving average on October 29, 2026 date and that indicates a change from a downward trend to an upward trend.
Following a +4.97% 3-day Advance, the price is estimated to grow further. Considering data from situations where SNY advanced for three days, in 152 of 304 cases, the price rose further within the following month. The odds of a continued upward trend are 50%.
Bearish Trend Analysis
The RSI Indicator demonstrated that the stock has entered the overbought zone. This may point to a price pull-back soon.
The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 6 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where SNY declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 52%.
SNY broke above its upper Bollinger Band on October 30, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for SNY entered a downward trend on October 22, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 8 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 52 (best 1 - 100 worst), indicating fairly steady price growth. SNY’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 78 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. SNY’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 60, placing this stock worse than average.
The Tickeron SMR rating for this company is 81 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Valuation Rating of 84 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.535) is normal, around the industry mean (-1.403). P/E Ratio (26.954) is within average values for comparable stocks, (21.451). SNY's Projected Growth (PEG Ratio) (27.976) is very high in comparison to the industry average of (5.738). SNY's Dividend Yield (0.179) is considerably higher than the industry average of (0.039). P/S Ratio (1.829) is also within normal values, averaging (4.033).
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a producer of pharmaceutical products
Industry PharmaceuticalsMajor
Advertisement